Metabolomics Creative Proteomics

Neurological Diseases Metabolomics Service

Neurological disorders, a small group of medical conditions that affect the nervous system, are more than 600 different diseases, including genetic disorders, infections, cancers, seizures (e.g., epilepsy), cardiovascular diseases (e.g., stroke), congenital and developmental disorders (e.g., spina bifida), and degenerative diseases (e.g., multiple sclerosis, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis).

Metabolomics is the qualitative and quantitative analysis of all small molecule metabolites in an organism or cell, and the search for relative relationships between metabolites and physiopathological changes.

Creative Proteomics is based on a variety of highly sensitive analytical techniques to identify metabolites involved in disease development by comparative assays analyzing metabolomic features in different samples from experimental and control groups. These differentially expressed substances can provide new insights into individual metabolic profiles to identify diagnostic or prognostic biomarkers, identify drug target candidates, or reveal potential new hypothesis-generating pathways. Studying the characteristic metabolic alterations in neurological diseases can help to understand the endogenous metabolic pathogenesis of the disease. Metabolomic markers also have the potential to improve diagnosis, patient follow-up, and clinical trial outcomes.

Neurological Diseases Metabolomics Solutions


Metabolomic analysis of central nervous system tumors

Analysis of metabolite differences between healthy individuals and glioma models. CNS tumor biomarker detection. Analysis of drug metabolism in drug development.


Metabolomic analysis of central nervous system trauma

Metabolic profiling to explore the mechanisms of CNS trauma.


Metabolomic analysis of Alzheimer's disease and related dementias

Metabolic profiling to investigate the pathogenesis of Alzheimer's disease. Comparative analysis of metabolite content changes in control and experimental groups. Biomarker detection.


Metabolomic analysis of amyotrophic lateral sclerosis/motor neuron disease

Metabolic profiling. Analysis of changes in metabolite levels in control and experimental groups. Biomarker detection.


Metabolomic analysis of Parkinson's disease and movement disorders

Metabolic profiling to investigate the pathogenesis of Parkinson's disease. Comparative analysis of metabolite content changes in control and experimental groups. Biomarker assay.

Metabolomics Analysis Process for Neurological Diseases

Neurological Diseases Metabolomics Service

Technology Platform for Metabolomics Analysis

Multiple analytical platforms, including GC-MS, LC-MS, UPLC-MS. Thousands of metabolites can be screened from a single biological sample, providing a comprehensive approach for probing disease mechanisms.

ChromatographyMass Spectrometry
GC (Q Exactive) (- mode MS)
HPLC: HILIC (+/- mode MS)
HPLC: RP C18 (+/-mode MS)
IC (- mode MS)
Q Exactive MS
Orbitrap Tribrid MS

Creative Proteomics is a well-established partner in biopharmaceutical research and has extensive experience in metabolomics analysis. We provide solutions for neurological diseases in the direction of metabolomics analysis, accelerating the exploration of new horizons in science. If you want to know more, please contact us. Looking forward to cooperating with you.

For Research Use Only. Not for use in diagnostic procedures.


Connect with Creative Proteomics Contact UsContact Us